Literature DB >> 17005820

Effect of tigecycline on normal oropharyngeal and intestinal microflora.

Carl Erik Nord1, Eva Sillerström, Elisabeth Wahlund.   

Abstract

Antibacterial agents disrupt the ecological balance of the normal human microflora. Tigecycline, a member of a new class of antibiotics (glycylcyclines), has been shown to have a potent broad-spectrum activity against most gram-positive and gram-negative aerobic and anaerobic bacteria. The aim of the study was to investigate the ecological effects of tigecycline on the normal oropharyngeal and intestinal microflora of healthy subjects. Thirteen healthy white subjects (six females and seven males) between 20 and 31 years of age received 100 mg of tigecycline in the morning on day 1 as a 30-min intravenous infusion followed by a 50-mg dose of tigecycline every 12 h as a 30-minute infusion for 10 days. One subject was withdrawn on day 2 because of an adverse event (urticaria). Serum, saliva, and fecal samples were collected before, during, and after administration for microbiological cultivation and for assays of tigecycline. All new colonizing bacteria were tested for susceptibility (resistance of > or =8 mg/liter) during the investigation period. The fecal concentrations on day 8 were from 3.0 to 14.1 mg/kg, with a mean value of 6.0 mg/kg and a median value of 5.6 mg/kg. The saliva concentrations were generally low (0 to 0.12 mg/liter). A minor effect on the oropharyngeal microflora was observed. The numbers of enterococci and Escherichia coli cells in the intestinal microflora were reduced at day 8 (P < 0.05), while those of other enterobacteria and yeasts increased. There was a marked reduction of lactobacilli and bifidobacteria (P < 0.05) but no impact on bacteroides. No Clostridium difficile strains were isolated. Two Klebsiella pneumoniae strains and five Enterobacter cloacae strains resistant to tigecycline were found on day 8.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005820      PMCID: PMC1610089          DOI: 10.1128/AAC.00373-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

Authors:  A C Gales; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

2.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

3.  In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline.

Authors:  C Edlund; C E Nord
Journal:  Clin Microbiol Infect       Date:  2000-03       Impact factor: 8.067

4.  Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.

Authors:  Gopal Muralidharan; Marlynne Micalizzi; John Speth; Donald Raible; Steven Troy
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 5.  Tigecycline.

Authors:  George A Pankey
Journal:  J Antimicrob Chemother       Date:  2005-07-22       Impact factor: 5.790

6.  Ecological effects on the oro- and nasopharyngeal microflora in children after treatment of acute otitis media with cefuroxime axetil or amoxycillin-clavulanate as suspensions.

Authors:  B Lund; C Edlund; B Rynnel-Dagöö; Y Lundgren; J Sterner; C E Nord
Journal:  Clin Microbiol Infect       Date:  2001-05       Impact factor: 8.067

Review 7.  Tigecycline: a novel glycylcycline.

Authors:  Ethan Rubinstein; David Vaughan
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

Authors:  P J Petersen; N V Jacobus; W J Weiss; P E Sum; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 9.  Effect of antimicrobial agents on the ecological balance of human microflora.

Authors:  A Sullivan; C Edlund; C E Nord
Journal:  Lancet Infect Dis       Date:  2001-09       Impact factor: 25.071

10.  Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora.

Authors:  C Edlund; G Beyer; M Hiemer-Bau; S Ziege; H Lode; C E Nord
Journal:  Scand J Infect Dis       Date:  2000
View more
  27 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

Review 2.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

3.  Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.

Authors:  Michael John Aldape; Dustin Delaney Heeney; Amy Evelyn Bryant; Dennis Leroy Stevens
Journal:  J Antimicrob Chemother       Date:  2014-08-23       Impact factor: 5.790

4.  Superinfection during treatment of nosocomial infections with tigecycline.

Authors:  E García-Cabrera; M E Jiménez-Mejías; M V Gil Navarro; M J Gómez-Gómez; C Ortiz-Leyba; E Cordero; J Pachón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-16       Impact factor: 3.267

5.  Case-control study of the risk factors for acquisition of Pseudomonas and Proteus species during tigecycline therapy.

Authors:  Ga Eun Park; Cheol-In Kang; Yu Mi Wi; Jae-Hoon Ko; Woo Joo Lee; Ji Yong Lee; Sun Young Cho; Young Eun Ha; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

6.  Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.

Authors:  Yi-Chun Lin; Yu-Tsung Huang; Pei-Jane Tsai; Tai-Fen Lee; Nan-Yao Lee; Chun-Hsing Liao; Shyr-Yi Lin; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

7.  Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.

Authors:  Robin L P Jump; Yuejin Li; Michael J Pultz; Georgios Kypriotakis; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

8.  Effect of antibiotic treatment on establishment and elimination of intestinal colonization by KPC-producing Klebsiella pneumoniae in mice.

Authors:  Federico Perez; Michael J Pultz; Andrea Endimiani; Robert A Bonomo; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

Review 9.  Tigecycline: in community-acquired pneumonia.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.

Authors:  Christine M Bassis; Casey M Theriot; Vincent B Young
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.